Your browser is no longer supported. Please, upgrade your browser.
Settings
SGEN [NASD]
Seagen Inc.
Index- P/E43.92 EPS (ttm)3.60 Insider Own0.70% Shs Outstand181.63M Perf Week9.53%
Market Cap27.50B Forward P/E1399.91 EPS next Y0.11 Insider Trans-15.74% Shs Float180.24M Perf Month0.58%
Income660.70M PEG1.12 EPS next Q-0.56 Inst Own95.60% Short Float1.33% Perf Quarter16.15%
Sales2.27B P/S12.10 EPS this Y451.20% Inst Trans6.62% Short Ratio2.98 Perf Half Y-4.73%
Book/sh18.67 P/B8.47 EPS next Y105.50% ROA16.00% Target Price189.13 Perf Year-6.42%
Cash/sh14.10 P/C11.22 EPS next 5Y39.20% ROE19.00% 52W Range133.20 - 213.94 Perf YTD-9.68%
Dividend- P/FCF36.36 EPS past 5Y41.20% ROI17.10% 52W High-24.73% Beta0.81
Dividend %- Quick Ratio6.80 Sales past 5Y45.20% Gross Margin88.90% 52W Low20.89% ATR4.44
Employees2092 Current Ratio7.10 Sales Q/Q39.70% Oper. Margin26.00% RSI (14)69.27 Volatility3.47% 2.90%
OptionableYes Debt/Eq0.00 EPS Q/Q-281.10% Profit Margin26.30% Rel Volume0.78 Prev Close158.19
ShortableYes LT Debt/Eq0.00 EarningsJul 29 AMC Payout0.00% Avg Volume804.44K Price161.03
Recom2.20 SMA209.60% SMA506.20% SMA200-0.30% Volume135,628 Change1.80%
May-17-21Initiated Evercore ISI In-line
Mar-31-21Initiated Credit Suisse Neutral $145
Feb-01-21Downgrade RBC Capital Mkts Outperform → Sector Perform $188 → $186
Jan-15-21Upgrade BofA Securities Neutral → Buy $215
Sep-22-20Reiterated Stifel Hold $145 → $165
Aug-24-20Resumed Berenberg Buy $187
Jul-31-20Reiterated H.C. Wainwright Buy $175 → $200
Jul-24-20Downgrade Piper Sandler Overweight → Neutral
May-26-20Initiated JMP Securities Mkt Outperform $185
May-01-20Upgrade Guggenheim Neutral → Buy
May-01-20Reiterated Needham Buy $157 → $163
Feb-18-20Downgrade Barclays Overweight → Equal Weight $124
Feb-12-20Reiterated H.C. Wainwright Buy $140 → $150
Feb-11-20Reiterated Goldman Buy $126 → $165
Jan-28-20Initiated BMO Capital Markets Outperform
Jan-27-20Initiated BMO Capital Markets Outperform
Jan-02-20Downgrade Guggenheim Buy → Neutral
Dec-10-19Initiated Morgan Stanley Equal-Weight
Dec-03-19Resumed BofA/Merrill Neutral
Oct-22-19Reiterated H.C. Wainwright Buy $98 → $140
Jul-30-21 10:03AM  
Jul-29-21 05:25PM  
04:02PM  
Jul-22-21 03:03PM  
Jul-09-21 02:10PM  
02:10PM  
Jul-08-21 08:00AM  
Jun-28-21 09:43AM  
Jun-16-21 06:38AM  
Jun-03-21 06:00AM  
Jun-02-21 08:00AM  
May-25-21 01:12PM  
May-19-21 05:00PM  
05:00PM  
Apr-30-21 03:01AM  
Apr-29-21 05:25PM  
04:02PM  
02:30PM  
08:00AM  
Apr-22-21 12:33PM  
Apr-19-21 08:00AM  
08:00AM  
Apr-16-21 07:07AM  
Apr-09-21 04:00PM  
04:00PM  
08:00AM  
Apr-07-21 08:00AM  
Mar-26-21 02:00AM  
Mar-18-21 06:02PM  
Mar-13-21 10:30AM  
Mar-05-21 08:00AM  
Feb-27-21 09:23AM  
Feb-24-21 08:00AM  
Feb-18-21 08:00AM  
08:00AM  
Feb-15-21 05:41AM  
Feb-12-21 02:15PM  
02:15PM  
02:15PM  
02:15PM  
10:28AM  
06:45AM  
05:31AM  
Feb-11-21 05:45PM  
04:02PM  
02:30PM  
Feb-10-21 04:05PM  
Jan-07-21 08:00AM  
Dec-30-20 12:04PM  
Dec-16-20 08:00AM  
03:18AM  
Dec-11-20 07:23AM  
Dec-08-20 08:00AM  
Dec-07-20 10:00AM  
Nov-11-20 03:15AM  
Nov-09-20 08:00AM  
Nov-05-20 08:00AM  
Nov-03-20 08:57AM  
06:17AM  
Nov-02-20 08:00AM  
Oct-30-20 01:07PM  
06:01AM  
Oct-29-20 06:05PM  
04:02PM  
Oct-28-20 08:00AM  
Oct-22-20 12:33PM  
12:27PM  
Oct-13-20 01:33PM  
08:00AM  
Oct-12-20 06:45AM  
06:45AM  
Oct-08-20 08:00AM  
Oct-07-20 09:44AM  
Oct-05-20 11:13AM  
Oct-03-20 06:55AM  
Oct-01-20 12:42PM  
Sep-28-20 05:33PM  
Sep-24-20 07:33AM  
Sep-21-20 10:20AM  
Sep-18-20 01:17PM  
12:38PM  
06:45AM  
06:45AM  
Sep-16-20 10:09AM  
09:47AM  
Sep-15-20 12:53PM  
09:51AM  
Sep-14-20 07:01PM  
05:40PM  
04:39PM  
04:34PM  
04:00PM  
03:55PM  
01:41PM  
12:48PM  
11:15AM  
10:30AM  
09:55AM  
09:51AM  
09:45AM  
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of metastatic urothelial cancers; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops Tisotumab Vedotin for metastatic cervical cancer and other solid tumors; ladiratuzumab vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and SpringWorks Therapeutics, Inc. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SIEGALL CLAY BPresident and CEOJul 02Option Exercise15.4615,268236,043722,621Jul 06 09:40 PM
ROMP CHARLES REVP, CommercialJul 02Sale158.41703111,36243,187Jul 06 08:13 PM
SIEGALL CLAY BPresident and CEOJul 02Sale156.3615,2682,387,233715,209Jul 06 09:40 PM
SIEGALL CLAY BPresident and CEOJul 01Option Exercise15.4614,085217,754721,374Jul 06 09:40 PM
SIEGALL CLAY BPresident and CEOJul 01Sale157.7814,0852,222,376715,209Jul 06 09:40 PM
DANSEY ROGER DChief Medical OfficerJun 16Sale152.2225,1093,822,03484,435Jun 21 06:02 PM
HIMES VAUGHN BChief Technical OfficerJun 07Option Exercise26.101,30334,00854,315Jun 08 08:50 PM
HIMES VAUGHN BChief Technical OfficerJun 07Sale150.001,303195,45053,012Jun 08 08:50 PM
HIMES VAUGHN BChief Technical OfficerJun 03Option Exercise15.4610,697165,37663,709Jun 04 08:21 PM
SIEGALL CLAY BPresident and CEOJun 03Option Exercise15.4629,353453,797723,884Jun 04 08:22 PM
SIEGALL CLAY BPresident and CEOJun 03Sale144.5129,3534,241,801715,209Jun 04 08:22 PM
HIMES VAUGHN BChief Technical OfficerJun 03Sale144.9110,6971,550,09053,012Jun 04 08:21 PM
ROMP CHARLES REVP, CommercialMay 17Sale145.9533448,74643,890May 19 07:10 PM
BAKER BROS. ADVISORS LPDirectorMay 14Option Exercise19.0235,000665,70043,307,671May 18 04:23 PM
LIU JEAN IGC/EVP, Leg AffairsMay 11Sale140.001,061148,54064,051May 13 07:17 PM
SIEGALL CLAY BPresident and CEOMay 06Option Exercise15.4629,353453,797733,288May 07 06:29 PM
SIEGALL CLAY BPresident and CEOMay 06Sale134.9729,3533,961,824715,209May 07 06:29 PM
SIEGALL CLAY BPresident and CEOApr 09Option Exercise15.4612,602194,827721,310Apr 09 08:13 PM
SIEGALL CLAY BPresident and CEOApr 09Sale141.9612,6021,788,924715,209Apr 09 08:13 PM
SIEGALL CLAY BPresident and CEOApr 08Option Exercise15.4616,751258,970724,376Apr 09 08:13 PM
SIEGALL CLAY BPresident and CEOApr 08Sale145.1716,7512,431,816715,209Apr 09 08:13 PM
SIEGALL CLAY BPresident and CEOMar 04Option Exercise15.4629,353453,797726,618Mar 05 07:56 PM
SIEGALL CLAY BPresident and CEOMar 04Sale145.7429,3534,277,763715,209Mar 05 07:56 PM
HIMES VAUGHN BChief Technical OfficerMar 02Option Exercise15.4612,000185,520141,889Mar 04 07:27 PM
HIMES VAUGHN BChief Technical OfficerMar 02Sale153.2212,0001,838,623129,889Mar 04 07:27 PM
LIU JEAN IGC/EVP, Leg AffairsFeb 17Option Exercise41.374,846200,46665,112Feb 18 08:48 PM
SIEGALL CLAY BPresident and CEOFeb 04Option Exercise15.4629,353453,797726,706Feb 05 08:00 PM
SIEGALL CLAY BPresident and CEOFeb 04Sale165.5729,3534,860,105715,209Feb 05 08:00 PM
LIU JEAN IGC/EVP, Leg AffairsJan 15Option Exercise35.955,000179,75065,266Jan 15 07:40 PM
LIU JEAN IGC/EVP, Leg AffairsJan 15Sale180.005,000900,00060,266Jan 15 07:40 PM
SIEGALL CLAY BPresident and CEOJan 07Option Exercise15.4629,353453,797719,687Jan 08 07:52 PM
SIEGALL CLAY BPresident and CEOJan 07Sale172.4429,3535,061,681715,209Jan 08 07:52 PM
SIMPSON TODD EChief Financial OfficerDec 18Option Exercise26.7134,773928,772152,436Dec 18 08:51 PM
SIMPSON TODD EChief Financial OfficerDec 18Sale200.0033,6696,733,800118,767Dec 18 08:51 PM
LIU JEAN IGC/EVP, Leg AffairsDec 16Option Exercise35.951,62458,38360,266Dec 16 07:41 PM
LIU JEAN IGC/EVP, Leg AffairsDec 14Option Exercise35.955,000179,75063,642Dec 16 07:41 PM
LIU JEAN IGC/EVP, Leg AffairsDec 14Sale195.865,000979,31658,642Dec 16 07:41 PM
SIEGALL CLAY BPresident and CEODec 07Option Exercise15.4615,723243,078720,265Dec 08 07:33 PM
HIMES VAUGHN BChief Technical OfficerDec 07Option Exercise25.3612,761323,646199,590Dec 09 08:08 PM
HIMES VAUGHN BChief Technical OfficerDec 07Sale181.768,0001,454,041191,590Dec 09 08:08 PM
SIEGALL CLAY BPresident and CEODec 07Sale181.1415,7232,848,122715,209Dec 08 07:33 PM
SIEGALL CLAY BPresident and CEODec 04Option Exercise15.4621,732335,977730,117Dec 08 07:33 PM
SIEGALL CLAY BPresident and CEODec 04Sale179.4321,7323,899,386715,209Dec 08 07:33 PM
SIEGALL CLAY BPresident and CEODec 03Option Exercise15.4621,253328,571726,145Dec 04 07:18 PM
ROMP CHARLES REVP, CommercialDec 03Option Exercise39.157,666300,12451,743Dec 03 05:45 PM
ROMP CHARLES REVP, CommercialDec 03Sale179.307,6661,374,51444,077Dec 03 05:45 PM
SIEGALL CLAY BPresident and CEODec 03Sale179.2821,2533,810,144715,209Dec 04 07:18 PM
ROMP CHARLES REVP, CommercialDec 01Option Exercise39.156,000234,90050,077Dec 03 05:45 PM
ROMP CHARLES REVP, CommercialDec 01Sale179.096,0001,074,53944,077Dec 03 05:45 PM
GRYSKA DAVID WDirectorNov 19Option Exercise19.0215,000285,30052,719Nov 23 08:11 PM
GRYSKA DAVID WDirectorNov 19Sale173.7015,0002,605,52344,848Nov 23 08:11 PM
SIMPSON TODD EChief Financial OfficerNov 05Sale180.377,5091,354,383118,767Nov 09 07:25 PM
GRYSKA DAVID WDirectorNov 05Sale180.604,500812,69944,848Nov 06 07:53 PM
ROMP CHARLES REVP, CommercialNov 04Option Exercise41.7414,079587,70349,228Nov 06 07:34 PM
ROMP CHARLES REVP, CommercialNov 04Sale180.3714,0792,539,42044,077Nov 06 07:34 PM
DANSEY ROGER DChief Medical OfficerNov 04Sale177.007,6611,356,020110,221Nov 05 09:38 PM
ROMP CHARLES REVP, CommercialNov 03Option Exercise19.245,19799,97947,719Nov 04 08:23 PM
LIPPMAN MARC EDirectorNov 03Option Exercise35.4762,7802,226,870144,432Nov 05 08:44 PM
LIPPMAN MARC EDirectorNov 03Sale168.61142,09023,958,28752,338Nov 05 08:44 PM
ROMP CHARLES REVP, CommercialNov 03Sale172.076,0611,042,93944,077Nov 04 08:23 PM
WELCH DANIEL GDirectorNov 02Option Exercise25.2149,5001,247,65271,098Nov 04 08:51 PM
WELCH DANIEL GDirectorNov 02Sale166.1358,7509,760,26047,348Nov 04 08:51 PM
ROMP CHARLES REVP, CommercialNov 02Sale166.7713,0012,168,12944,941Nov 04 08:23 PM
LIU JEAN IGC/EVP, Leg AffairsSep 21Option Exercise36.779,954366,01958,642Sep 23 07:28 PM
LIU JEAN IGC/EVP, Leg AffairsSep 14Sale170.0011,6101,973,70048,688Sep 16 06:53 PM
HIMES VAUGHN BChief Technical OfficerSep 09Option Exercise15.468,000123,680194,829Sep 11 06:25 PM
HIMES VAUGHN BChief Technical OfficerSep 09Sale147.558,0001,180,385186,829Sep 11 06:25 PM
SIMPSON TODD EChief Financial OfficerSep 01Sale155.8612,0911,884,512126,276Sep 02 07:24 PM
DANSEY ROGER DChief Medical OfficerAug 31Sale155.694,611717,906117,882Sep 02 07:25 PM
SIEGALL CLAY BPresident and CEOAug 31Sale155.6914,3512,234,367715,209Sep 02 07:24 PM
HIMES VAUGHN BChief Technical OfficerAug 31Sale155.693,585558,164186,829Sep 02 07:25 PM
SIMPSON TODD EChief Financial OfficerAug 31Sale155.694,187651,892138,367Sep 02 07:24 PM
ROMP CHARLES REVP, CommercialAug 31Sale155.691,133176,40257,942Sep 02 07:25 PM
LIU JEAN IGC/EVP, Leg AffairsAug 31Sale155.693,648567,97260,298Sep 02 07:25 PM
SIEGALL CLAY BPresident and CEOAug 21Option Exercise19.4210,299199,984729,560Aug 25 06:35 PM
LIU JEAN IGC/EVP, Leg AffairsAug 18Sale158.176,8461,082,82363,946Aug 20 06:58 PM
ROMP CHARLES REVP, CommercialAug 18Sale158.174,027636,94159,075Aug 20 06:26 PM
SIEGALL CLAY BPresident and CEOAug 18Sale158.1727,0604,280,053719,261Aug 20 06:26 PM
SIMPSON TODD EChief Financial OfficerAug 18Sale158.179,2621,464,959142,554Aug 20 06:27 PM
HIMES VAUGHN BChief Technical OfficerAug 18Sale158.178,0541,273,892190,414Aug 20 06:23 PM
DANSEY ROGER DChief Medical OfficerAug 17Sale157.7945071,006122,493Aug 17 09:40 PM
SIEGALL CLAY BPresident and CEOAug 10Option Exercise12.0028,475341,700729,955Aug 13 06:04 AM
SIEGALL CLAY BPresident and CEOAug 10Sale156.7428,4754,463,263718,339Aug 13 06:04 AM